N-(furan-2-yl(8-hydroxy-5-nitroquinolin-7-yl)methyl)propionamide | 503838-02-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(furan-2-yl(8-hydroxy-5-nitroquinolin-7-yl)methyl)propionamide
• 英文别名: N-[(Furan-2-YL)(8-hydroxy-5-nitroquinolin-7-YL)methyl]propanamide；N-[furan-2-yl-(8-hydroxy-5-nitroquinolin-7-yl)methyl]propanamide
• CAS: 503838-02-6
• 化学式: C₁₇H₁₅N₃O₅
• 分子量: 341.323
• InChiKey: NVKXHMNIODKIRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] INHIBITORS OF HUMAN 12-LIPOXYGENASE<br/>[FR] INHIBITEURS DE LA 12-LIPOXYGÉNASE HUMAINE
  申请人：US HEALTH

  公开号：WO2011146618A1

  公开（公告）日：2011-11-24

  Disclosed are inhibitors of human 12-lipoxygenase of Formula (I) or (II), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating or preventing a 12-lipoxygenase mediated disease or disorder, e.g., diabetes. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal.

  本发明涉及一种公式（I）或（II）的人类12-脂氧合酶抑制剂，其中R1、R2、R3和R4的定义如本文所述，该抑制剂可用于治疗或预防12-脂氧合酶介导的疾病或紊乱，例如糖尿病。本发明还涉及一种包含药学上可接受载体和至少一种本发明的抑制剂的组合物，以及一种用于治疗或预防哺乳动物中该疾病或紊乱的方法。
• [EN] INHIBITORS OF JMJD2C AS ANTICANCER AGENTS<br/>[FR] INHIBITEURS DE JMJD2C UTILISÉS EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：DAVID GLADSTONE INST

  公开号：WO2015167874A1

  公开（公告）日：2015-11-05

  The present disclosure provides compounds, pharmaceutical compositions and related methods for the treatment of cancer, e.g., castration-resistant prostate cancer (CRPC). Specifically, the present disclosure provides a series of 8-hydroxyquinoline derivatives which show cytotoxic effects on androgen-independent prostate cancer cells.

  本公开提供了化合物、制药组合物和相关方法，用于治疗癌症，例如去势抵抗性前列腺癌（CRPC）。具体而言，本公开提供一系列8-羟基喹啉衍生物，其对雄激素非依赖性前列腺癌细胞具有细胞毒性作用。
• INHIBITORS OF HUMAN 12-LIPOXYGENASE
  申请人：The U.S.A. as represented by the Secretary, Department of Health and Human Services

  公开号：EP2571853A1

  公开（公告）日：2013-03-27
• INHIBITORS OF JMJD2C AS ANTICANCER AGENTS
  申请人：The J. David Gladstone Institutes

  公开号：EP3137079A1

  公开（公告）日：2017-03-08
• Inhibitors of JMJD2C as Anticancer Agents
  申请人：The J. David Gladstone Institutes

  公开号：US20170044107A1

  公开（公告）日：2017-02-16

  The present disclosure provides compounds, pharmaceutical compositions and related methods for the treatment of cancer, e.g., castration-resistant prostate cancer (CRPC). Specifically, the present disclosure provides a series of 8-hydroxyquinoline derivatives which show cytotoxic effects on androgen-independent prostate cancer cells.